Skip to main content
. 2017 Apr 15;9(4):1783–1791.

Figure 5.

Figure 5

Downregulation of usp9x increased cisplatin sensitivity in breast cancer cells. After transfection with usp9x siRNA or negative control, breast cancer cell lines (MDA-MB-231, MDA-MB-468 and Bcap-37) were exposed to cisplatin at different concentrations (0, 2, 4, 6, 8, 10 μg/mg). Viability of (A) MDA-MB-231, (B) MDA-MB-468, and (C) Bcap-37 cells was determined using CCK-8 assay. (D) Western blot was performed to measure the protein expression of usp9x and Mcl-1 in MDA-MB-231, MDA-MB-468, and Bcap-37 cells. * vs. control, P < 0.05.